The full analyst notes on Biogen are available to download free of charge at: http://www.analystsreview.com/1687-BIIB-28Apr2014.pdf Bristol-Myers Squibb Co. Analyst Notes On April 22, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) and Samsung BioLogics (Samsung) jointly announced that they will increase the scope of their existing manufacturing agreement under which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Bristol-Myers and Samsung signed their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance. The financial terms of the agreement were not disclosed.